Dr. Reddy’s Laboratories received a positive opinion from the European Medicines Agency for their biosimilar AVT03, a generic version of Prolia and Xgeva. The company plans to submit a Marketing Authorisation Application to the UK MHRA separately. Dr. Reddy’s entered a partnership with Alvotech for the development and commercialization of AVT03, with Alvotech handling manufacturing and Dr. Reddy’s taking care of registration and sales in the U.S. and Europe. For more health news, visit rttnews.com. Please note that the views expressed in the article are those of the author and not Nasdaq, Inc.

Read more at Nasdaq: Dr. Reddy’s Receives Positive CHMP Opinion For AVT03